{"filing":{"accession_number":"0001193125-26-274139","cik":"0001835579","ticker":"IMA","company_name":"ImageneBio, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"d114862d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526274139/d114862d8k.htm"},"events":[{"id":11545,"run_id":10140,"accession_number":"0001193125-26-274139","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"ImageneBio held its Annual Meeting on June 16, 2026, with shareholders voting on three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Equity Incentive Plan.","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8151,"accession_number":"0001193125-26-274139","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This Item 5.02(e) discloses stockholder approval of an amendment and restatement of the 2025 Equity Incentive Plan, increasing authorized shares by 850,000 and modifying the calculation of annual automatic share reserve increases. This is a compensatory arrangement disclosure under Item 5.02(e), as it directly affects the equity compensation framework available to directors and officers. The materiality is high given the substantial increase in authorized shares and the modification to the plan's mechanics.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:07.884728+00:00","company_name":"","ticker":null,"filing_date":""},{"id":8152,"accession_number":"0001193125-26-274139","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from ImageneBio's Annual Meeting held on June 16, 2026, covering three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Plan. The tabulated vote counts for each proposal are the core content of a shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:07.884728+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8151,"accession_number":"0001193125-26-274139","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This Item 5.02(e) discloses stockholder approval of an amendment and restatement of the 2025 Equity Incentive Plan, increasing authorized shares by 850,000 and modifying the calculation of annual automatic share reserve increases. This is a compensatory arrangement disclosure under Item 5.02(e), as it directly affects the equity compensation framework available to directors and officers. The materiality is high given the substantial increase in authorized shares and the modification to the plan's mechanics.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:07.884728+00:00","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-06-17"},{"id":8152,"accession_number":"0001193125-26-274139","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the final voting results from ImageneBio's Annual Meeting held on June 16, 2026, covering three proposals: election of two Class II directors (David P. Bonita and Joseph P. Slattery), ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of the 2025 Amended Plan. The tabulated vote counts for each proposal are the core content of a shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:09:07.884728+00:00","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-06-17"}]}